Kura Oncology (KURA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Kura Oncology Reports Second Quarter 2023 Financial Results
August 3, 2023 4:05 PM EDTEnrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections
First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML
Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA
Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC
First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023
$477 million in cash, equivalents and investments provide runway to mid-2026
Management to host webcast and... More
